Series B: ImCheck Therapeutics receives USD 53 million
Antwerp (BE) / Marseille (FR) — In a Series B financing round totaling $53 million, Gimv has increased its stake in ImCheck Therapeutics, an emerging provider of oncology and autoimmune therapy solutions based in France. The round is led by Pfizer Ventures (NYSE: PFE) and Bpifrance and will be joined by new investors. In addition to Gimv, existing investors Life Sciences Partners (LSP), Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund also participated to a significant extent in the increase.
The Series B round funds will be used to finance initial clinical trials of ImCheck Therapeutics’ first-in-class monoclonal antibody ICT01. For example, the broad pipeline of immunomodulators for the so-called butyrophilin superfamily will be further expanded and new antibody therapies in the field of immuno-oncology will be made available to clinics.
Bram Vanparys, Partner at Gimv and responsible for the investment on the Health & Care platform, says: “ImCheck has made significant progress since our investment in the Series A round. As a result, we are pleased to have attracted a number of new notable investors from the U.S. and Europe for the Series B round. Gimv’s significant investment in this financing round demonstrates the potential in ImCheck’s pipeline of solutions for the oncology and autoimmune therapy space.”
Gimv is a European investment company with almost 40 years of experience in private equity. The company is listed on Euronext Brussels, currently manages around EUR 1.2 billion and currently invests in 50 portfolio companies, which together realize a turnover of more than EUR 2.5 billion and employ 14,000 people.
Gimv identifies innovative, leading companies with high growth potential and supports them on their way to market leadership. Each of the four investment platforms Connected Consumer, Health & Care, Smart Industries and Sustainable Cities is managed by a dedicated and competent team, each based in Gimv’s home markets — Benelux, France and DACH — and supported by an extensive international network of experts. www.gimv.com